Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals Inc (NY: AMRX )

4.290 +0.110 (+2.63%)
Official Closing Price Updated: 7:00 PM EDT, Sep 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,158,702
Open 4.130
Bid (Size) 4.200 (3)
Ask (Size) 4.350 (1)
Prev. Close 4.180
Today's Range 4.127 - 4.360
52wk Range 1.240 - 4.730
Shares Outstanding 1,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Amneal Receives U.S. FDA Approval for Calcium Gluconate Injection
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Analyst Ratings for Amneal Pharmaceuticals
Via Benzinga

Performance

YTD
+103.32%
+103.32%
1 Month
+5.15%
+5.15%
3 Month
+49.48%
+49.48%
6 Month
+237.80%
+237.80%
1 Year
+98.61%
+98.61%

More News

Read More
Amneal Receives First Product Approval in China
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Pharmaceuticals's Earnings: A Preview
Via Benzinga
Why Shares of Amneal Pharmaceuticals Are Plunging Wednesday
Via The Motley Fool
Delegation from U.S. Department of Health and Human Services, U.S. Food and Drug Administration, and Local Government Officials Visit Amneal Manufacturing Site in India
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Participate at the 2023 Wells Fargo Healthcare Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
JAMA Neurology Publishes Phase 3 Study Results Comparing IPX203 to Immediate-Release Carbidopa/Levodopa for Parkinson’s Disease
From Amneal Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why ResMed Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Atlassian, Universal Display, Booking, Dropbox And Other Big Stocks Moving Higher On Friday
Via Benzinga
Amneal Pharmaceuticals Stock Gaines: It Raised FY23 Outlook On Prescription Trends, Pricing Levels Strength
Via Benzinga
Amneal Reports Second Quarter 2023 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For August 4, 2023
Via Benzinga
Amneal Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report Second Quarter 2023 Results on August 4, 2023
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Crude Oil Rises Sharply; Impel Pharmaceuticals Shares Spike Higher
Via Benzinga
Dow Drops 150 Points; US Factory Orders Increase 0.3% In May
Via Benzinga
Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
FDA Strikes Out Amneal Pharmaceuticals' Parkinson's Disease Candidate, Stock Falls
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Receives U.S. FDA Complete Response Letter for IPX203
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.